Efficacy and safety of selective cyclin-dependent kinases 4/6 inhibitors in hormone-receptor-positive, HER2-negative advanced breast cancer – results from a real-world setting

Efficacy and safety of selective cyclin-dependent kinases 4/6 inhibitors in hormone-receptor-positive, HER2-negative advanced breast cancer – results from a real-world setting

Background: Selective cyclin-dependent kinases 4/6 inhibitors (CDKi) have become the standard of care in patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer (ABC). We performed retrospective analysis in patients treated with CDKi in the first year of their routine clin...

Full description

Bibliographic Details
Main Authors: ANJA KOVAČ, Erika Matos, Cvetka Grašič Kuhar, Marina Čakš, Tanja Ovčariček, Marina Mencinger, Mojca Humar, Simona Borštnar
Format: Article
Language:English
Published: Elsevier 2020-01-01
Series:Cancer Treatment and Research Communications
Subjects:
Hr-positive
Her2-negative advanced breast cancer
Cyclin-dependent kinases 4/6 inhibitors
Real-world evidence
Time-to-treatment failure
Overall survival
Online Access:http://www.sciencedirect.com/science/article/pii/S2468294220300381

Internet

http://www.sciencedirect.com/science/article/pii/S2468294220300381

Similar Items